Vascular effects of lipopolysaccharide are enhanced in interleukin-10- deficient mice

Stroke

Volumn 30, Issue 10, 1999, Pages 2191-2196

  Gunnett, Carol A ^a   Berg, Daniel J ^a   Faraci, Frank M ^a,b  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

Acetylcholine; Endothelium; Inducible NO synthase; Nitric oxide

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; AMINOGUANIDINE; INTERLEUKIN 10; LIPOPOLYSACCHARIDE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE INHIBITOR; PHENYLEPHRINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTERY CONSTRICTION; ARTICLE; BLOOD VESSEL REACTIVITY; BLOOD VESSEL TONE; CAROTID ARTERY; CONTROLLED STUDY; GENE DELETION; GENE TARGETING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 0032875348     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.30.10.2191     Document Type: Article

References (20)

1. Goldman M, Stordeur P. Interleukin-10 as an anti-stress cytokine. Eur Cytokine Netw. 1997;8:301-302.
2. Berg DJ, Kuehn R, Rajewsky K, Mueller W, Menon S, Davidson N, Gruenig G, Rennick D. Interleukin-10 is a central regulator of the response to LPS in murine models of endotoxic shock and the Shwartzman reaction but not endotoxin tolerance. J Clin Invest. 1995;96: 2339-2347.
3. Becherel PA, Le Goff L, Ouaaz F, Mencia-Huerta JM, Dugas B, Debre P, Mossalayi MD, Arock M. Interleukin-10 inhibits IgE-mediated nitric oxide synthase induction and cytokine synthesis in normal human keratinocytes. Eur J Pharmacol. 1995;25:2992-2995.
4. -/- mice: an overview. J Leukocyte Biol. 1997;61:389-396.
5. Raisanen-Sokolowski A, Mottram PL, Glysing-Jensen T, Satoskar A, Russell ME. Heart transplant in interferon-γ, interleukin 4, and interleukin 10 knockout mice: recipient environment alters graft rejection. J Clin Invest. 1997;100:2449-2456.
6. Kuhn R, Lohler J, Rennick D, Rajewsky K, Muller W. Interleukin-10-deficient mice develop chronic enterocolitis. Cell. 1993;75:263-274.
7. Vallance P, Collier J. Biology and clinical relevance of nitric oxide. Br Med J. 1994;309:453-457.
8. Gunnett CA, Chu Y, Heistad DD, Loihl A, Faraci FM. Vascular effects of LPS in mice deficient in expression of the gene for inducible nitric oxide synthase. Am J Physiol. 1998;275:H416-H421.
9. Misko TP, Moore WM, Kasten TP, Nickols GA, Corbett JA, Tilton RG, McDaniel ML, Williamson JR, Currie MG. Selective inhibition of the inducible nitric oxide synthase by aminoguanidine. Eur J Pharmacol. 1993;233:119-125.
10. Thorin-Trescases N, Hamioton CA, Reid JL, McPherson KL, Jardine E, Berg G, Bohr D, Dominiczak AF. Inducible L-arginine/nitric oxide pathway in human internal mammary artery and saphenous vein. Am J Physiol. 1995;268:H1122-H1132.
11. Griffiths MJD, Liu S, Messent CM, Evans TW. In vivo treatment with endotoxin induces nitric oxide synthase in rat main pulmonary artery. Am J Physiol. 1995;268:L509-L518.
12. Bonthu S, Heistad DD, Chappell DA, Lamping KG, Faraci FM. Atherosclerosis, vascular remodeling, and impairment of endothelium-dependent relaxation in genetically altered hyperlipidemic mice. Arterioscler Thromb Vasc Biol. 1997;17:2333-2340.
13. Faraci FM, Sigmund CD, Shesely EG, Maeda N, Heistad DD. Responses of carotid artery in mice deficient in expression of the gene for endothelial NO synthase. Am J Physiol. 1998;274:H564-H570.
14. Wolff DJ, Lubeskie A. Aminoguanidine is an isoform-selective, mechanism-based inactivator of nitric oxide synthase. Arch Biochem Biophys. 1995;316:290-301.
15. Southan GJ, Szabo C. Selective pharmacological inhibition of distinct nitric oxide synthase isoforms. Biochem Pharmacol. 1996;51:383-394.
16. + channels. J Pharmacol Exp Ther. 1996;279:1514-1519.
17. Nakane M, Klinghofer V, Kuk JE, Donnelly JL, Budzik GP, Pollock JS, Basha F, Carter GW. Novel potent and selective inhibitors of inducible nitric oxide synthase. Mol Pharmacol. 1995;47:831-834.
18. Uyemura K, Demer LL, Castle SC, Jullien D, Berliner JA, Gately MK, Warrier RR, Pham N, Fogelman AM, Modlin RL. Cross-regulatory roles of interleukin (IL)-12 and IL-10 in atherosclerosis. J Clin Invest. 1996; 97:2130-2138.
19. Wong M-L, Bongiorno PB, Rettori V, McCann SM, Licinio J. Interleukin (IL) 1β, IL-1 receptor antagonist, IL-10, and IL-13 gene expression in the central nervous system and anterior pituitary during systemic inflammation: pathophysiological implications. Proc Natl Acad Sci U S A. 1997; 94:227-232.
20. Hickey MJ, Issekutz AC, Reinhardt PH, Fedorak RN, Kubes P. Endogenous interleukin-10 regulates hemodynamic parameters, leukocyte-endothelial cell interactions, and microvascular permeability during endotoxemia. Circ Res. 1998;83:1124-1131.